Rhabdomyolysis: A Rare Adverse Effect of Levetiracetam
| Autor: | Devina Singh, Vaibhav Rastogi, Babbaljeet Kaur, Pulkit Arora, Jaya P Gadikota |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
levetiracetam
Urinary incontinence 03 medical and health sciences 0302 clinical medicine adverse effect medicine Internal Medicine 030212 general & internal medicine Adverse effect biology business.industry General Engineering medicine.disease Discontinuation Anesthesia biology.protein Vomiting rhabdomyolysis Creatine kinase Levetiracetam medicine.symptom business Hyponatremia Rhabdomyolysis 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Cureus |
| ISSN: | 2168-8184 |
| Popis: | Levetiracetam is an anti-epileptic that works at the synapse and binds synapse vesicle protein 2A, thereby controlling the release of neurotransmitters. Its side effects mainly include somnolence, headache, fatigue, dizziness, vomiting, and behavioral alterations. Rhabdomyolysis is a rare adverse effect of levetiracetam. The underlying pathophysiology of this adverse effect is unknown. Our patient is a 42-year-old male who was brought to the hospital with a complaint of generalized tonic-clonic seizures and urinary incontinence. His symptoms were caused by hyponatremia. Levetiracetam was started for seizure prevention along with management for hyponatremia. His creatine phosphokinase levels increased on the third day of admission to 30,000 U/L. Four days after the discontinuation of levetiracetam and with the institution of supportive therapy, the patient's rhabdomyolysis resolved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|